Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
|Videos|March 14, 2017
Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma
Author(s)David J. Straus, MD
David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.
Advertisement
David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.
Advertisement
Related to this article
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5